Short Wave Short Wave

Without this pill, lots of people would be dead

May 11, 2026 · 14m

Summary

This episode marks the 25th anniversary of Gleevec, a targeted therapy that revolutionized cancer care by turning chronic myeloid leukemia from fatal to survivable. Hosts Emily Kwong and Sydney Lufkin explore the drug’s origin, highlighting oncologist Brian Druker’s pioneering work and the collaborative effort between researchers, Novartis, and the FDA. The story features patient Mel Mann, who defied a three-year prognosis to live a full life, illustrating how Gleevec ushered in an era of personalized medicine.

Topics discussed

Intro: Tiny Desk Contest Tour and Shortwave welcome Mel Mann's story: From terminal diagnosis to marathon runner Sponsors: NetSuite and Edward Jones The origin of Gleevec: Dr. Brian Druker's targeted therapy idea Clinical trials: Unprecedented success and patient demand Fast-track approval: Collaboration between NIH, FDA, and Novartis Legacy of Gleevec: Targeted therapies and other cancers Where are they now: Updates on Mel, Insa, and Dr. Druker Outro: Credits and related episode recommendation Trailers: Mint Mobile, Up First, and Fresh Air

More from Short Wave

This gas station drug acts like opioids. It’s getting harder to buy
Nov 20, 2026
How a viral video gave a huge boost to new gene therapy
Nov 18, 2026
How bird poop and manta rays sustain a pristine coral reef
Nov 17, 2026
Are your body clocks off? Meet ‘circadian depression’
Nov 16, 2026
AI could help hospitals diagnose PTSD in real time
Nov 13, 2026
Listen ad-free on Castria